Overview

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Status:
RECRUITING

Trial end date:
2027-10-01

Target enrollment:

Participant gender:

Summary

Efbemalenograstim alfa for primary/secondary prevention in patients with solid tumors at high risk for febrile neutropenia (FN) or Intermediate risk of chemotherapy regimens associated with other risk factors in FN

Phase:

PHASE2

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborator:

West China Hospital